CA 19-9 as a Marker for Gastrointestinal Cancers: A Review

Koprowski H Steplewski Z Mitchell K Herlyn M Herlyn D Fulner P . Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957–72

Magnani J Nilson B Brockhaus M Smith DF Ginsburg V Blaszcyk M . A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopenteose II. J Biol Chem 1982; 257: 14365–9

Itkowitz SH Kim YS . New carbohydrate tumor markers. Gastroenterology 1986; 90: 491–6

Ho JJL Kim YS . Do mucins promote tumor cell metastasis? (Review). Int J Oncol 1995; 7: 913–26

Wesseling J van der Valk SW Hilkens J . A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565–77

Gimmi CD Morrison BW Mainprice BA Gribben JG Boussiotis V Freeman G . Breast cancer-associated antigen, DF3/MUCI, induces apoptosis of activated human T cells. Nature Med 1996; 2: 1367–70

Del Villano BC Brennan S Brock P Bucher C Liu V MaClure M . Radioimmunometric assay for a monoclonal antibody-defined tumor marker. Clin Chem 1983; 29; 549–52

Steinberg W . The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterology 1990; 85; 350–5

Duffy MJ . New cancer markers. Ann Clin Biochem 1989; 26: 379–87

Rosewicz S Wiedenmann B . Pancreatic carcinoma. Lancet 1997 349: 485–9

Malesci A Tommasini MA Bonato C Bocchia P Bersan M Zerbi A . Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92: 60–70

Moossa AR Gemagami RA . Diagnosis and staging of pancreatic neoplasms. Surg Clin N Am 1995; 75: 871–90

Duffy MJ O'Sullivan F O'Donoghue D Afdhal N Kelleher D . CA 19-9, a new marker for gastrointestinal malignancy. Ir J Med Sci 1985; 154: 385–6

Steinberg WM Gelfand R Anderson KK Glen J Kurtzman SH Sindelar WE . Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assay in detecting cancer of the pancreas. Gastroenterology 1986; 90: 343–9

Ritts RE Del Villano BC Go N Herberman R Klug T Zurawski VR . Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer 1984; 33: 339–45

Pleskow DK Berger HJ Gyves J Allen E McLean A Podolsky DK . Evaluation of a serological marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704–9

Sakahara H Endo K Nakajima K Nakashima T Koizumi M Ohta H . CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57: 1324–6

DelMaschio A Vanzulli A Sironi S Castrucci M Mellone R Staudacher C . Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT and CT-guided fine-needle biopsy. Radiol 1991; 178: 95–9

Glen J Steinberg WM Kurtzman SH Sternberg SM . Evaluation of the utility of a radioimmunoassay for serum CA 9-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462–8

Tian F Appert HE Myles J Howard JM . Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 218: 350–5

Gattini AM Mandeli J Bruckner HW . Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78: 57–62

Beastall GH Cook B Rustin GJS Jennings J . A review of the role of established tumour markers. Ann Clin Biochem 1991; 28: 5–18

Beretta E Malesci A Zerbi A Mariam A Carbucci M Bonato C . Serum CA 19-9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 7428–31

Kuusela P Jalanko H Roberts P Sipponen P Mecklin J-P Pitkanen R . Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer 1984; 49: 135–9

Von Kleist S Hesse Y Kananeeh H . Comparative evaluation of 4 tumor markers, CA 242, CA 19-9, TPA and CEA in carcinomas of the colon. Anticancer 1996; 16: 2325–32

Staab HJ Brummendorf A Hornung A Anderer FA Kieninger G . The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klin Wochenschr 1985; 63: 106–15

Fileila X Molina R Pique JM Garcia-Valdecasas JC Grau JJ Novell F . Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumor Biol 1994; 18: 1–6

Anonymous. Clinical Practice Guidelines for the use of tumor markers in breast and colorectal cancer [Special Article]. J Clin Oncol 1996; 14: 2843–77

Shimono R Mori M Akazawa K Adachi Y Sgimachi K . Immuno-histochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma. Am J Gastroenterol 1994; 89: 101–5

Heptner G Domschke S Domschke W . Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. Scand J Gastroenterol 1989; 24: 745–50

Safi F Berger HG Bittner R Buchler M Krautzberger W . CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779–83

Ramage JK Donaghy A Farrant JM Iorns R Williams R . Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865–9

Fabris C Bass O Leandro G Meggiato T Elba S Panozzo MP , Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis. Cancer 1991; 68: 1795–8

Satake K Kanazawa G Kho I Chung Y Umeyama K . Evaluation of serum pancreatic enzymes, carbohydrate antigen CA 19-9 and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 1985; 80: 630–6

Haglund C Roberts PJ Kuusela P Scheinin TM Makela D Jalanko H . Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197–202

Collazos J Genolla J Ruibal A . CA 19-9 in nonneoplastic liver disease. A clinical and laboratory study. Clin Chim Acta 1992; 210: 145–51

Duffy MJ O'Sullivan F McDonnell TJ Fitzgerald MX . Increased concentration of antigen CA 19-9 in serum of cystic fibrosis patients. Clin Chem 1985; 31: 1245–6

Arakawa Y Ariga H Kano M Matsho Y Honda T Morita K . Determination and clinical significance of a new carbohydrate antigen in digestive system cancers. Jpn J Med 1985; 24: 121–9

Craxi A Patti C Aragona E . Serum CA 19-9 levels in patients with hepatocellular carcinoma or cirrhosis. Ital J Gastroenterol 1985; 17: 288–9

Albert MB Steinberg WM Henry JP . Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988; 33: 1223–5

Zucchelli GC Pilo A Chiesa MR Cohen R Bizollon CA . Growing use of non-isotopic CA 19-9 immunoassays increase between laboratory variability. Clin Chem 1995; 39: 909–11

Pizo A Zucchelli GC Cohen R Chiesa MR Bizollon CA . Performance of immunoassays for CA 19-9, CA 15-3 and CA 123 tumour markers evaluated from an International Quality Assessment Survey. Eur J Clin Chem Biochem 1996; 34: 145–50

Plebani M Giacomini A Beghi L De Paoli M Roveroni G Galeotti F . Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996; 16: 2249–52